Figure 6.

(A) Kaplan-Meier graphs showing progression-free survival after ¹³¹I-tositumomab therapy in non-Hodgkin's lymphoma patients (A), compared with best results from other therapies (B) and chemotherapies (C). (B) Overall survival in patients with high-risk radioresistant medullary thyroid cancer after pretargeted radioimmunotherapy. Vertical bars correspond to a 95% confidence interval for survival rate at the median follow-up (reproduced with permission from Liu et al. ⁴¹ and Chatal et al. ²⁴ ).